Welcome to our dedicated page for Clover Health Investments SEC filings (Ticker: CLOV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Clover Health Investments, Corp. (Nasdaq: CLOV) SEC filings page on Stock Titan provides centralized access to the company’s regulatory disclosures as a publicly traded Medicare Advantage and healthcare technology issuer. Clover Health files reports with the U.S. Securities and Exchange Commission that describe its Medicare Advantage insurance operations, technology platform, financial performance, risk factors, and governance.
Investors can review current reports on Form 8-K, where Clover Health announces material events such as quarterly financial results, CMS Star Ratings for its Medicare Advantage PPO and HMO plans, and board or governance changes. Some 8-K filings also reference supplemental written responses to shareholder questions, offering additional context on strategy, cohort economics, and the role of Clover Assistant and Counterpart Health in the business.
In addition to 8-Ks, Clover Health’s annual reports on Form 10-K and quarterly reports on Form 10-Q (when available in the feed) typically provide detailed discussions of its Insurance segment, Medicare Advantage membership trends, non-GAAP measures such as Adjusted EBITDA and Insurance Benefits Expense Ratio, and regulatory considerations related to Medicare, CMS Star Ratings, and value-based care arrangements.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand how items such as Star Rating changes, CMS rate updates, or shifts in membership mix may affect Clover Health’s reported results. Users can also track insider transaction reports on Form 4 when they appear, to monitor equity transactions by directors and officers.
Filings are updated in near real time from the SEC’s EDGAR system, allowing investors, analysts, and other stakeholders to follow Clover Health’s evolving disclosures on Medicare Advantage performance, technology initiatives through Clover Assistant and Counterpart Health, and corporate governance developments.
Clover Health Investments (CLOV)Chelsea Clinton resigned from its Board of Directors and its Talent and Compensation and Nominating and Corporate Governance Committees, effective October 31, 2025. The company states her decision was not due to any disagreement regarding operations, policies, or practices.
The Board’s authorized size remains nine directors, and it will continue to operate with two vacant seats following her departure. The Board intends to fill the vacancy as soon as practicable.
Clover Health (CLOV) reported an insider transaction by its CEO, Medicare Advantage, Jamie L. Reynoso. On 10/17/2025, Reynoso sold 16,514 Class A shares in open market transactions at a $2.69 weighted average price, with trade prices ranging from $2.65 to $2.72. The sale was executed under a Rule 10b5-1 trading plan adopted on March 13, 2025.
Following the sale, Reynoso beneficially owns 2,955,226 shares, held directly.
Clover Health (CLOV) executive Brady Priest (CEO of Home Care) reported a tax‑withholding transaction on October 18, 2025. The filing shows 48,305 shares of Class A common stock were automatically withheld at $2.71 per share upon RSU vesting (Transaction Code F), leaving 2,340,274 shares beneficially owned directly.
The shares relate to vesting of 6.25% of time‑based RSUs granted on July 18, 2022. The remaining RSUs have a final vesting date on July 18, 2026, contingent on continued service.
Clover Health Investments, Corp. (CLOV) reported an insider transaction on a Form 4. An officer (CEO of Home Care) had 82,778 shares of Class A Common Stock automatically withheld at $2.8 on 10/15/2025 to cover taxes from restricted stock unit (RSU) vesting (Transaction Code F).
Following the withholding, the reporting person directly beneficially owns 2,388,579 shares. The RSUs were granted on 10/15/2024; 25% vested on 10/15/2025, with the remainder vesting quarterly in 6.25% increments through 10/15/2028, subject to continued service.
Clover Health (CLOV) reported an insider transaction by CEO and Director Andrew Toy. On 10/15/2025, 242,580 shares of Class A Common Stock were withheld at $2.8 per share (transaction code F) to cover tax obligations arising from RSU vesting. Following this administrative withholding, Toy beneficially owns 9,922,982 shares directly.
The withheld shares relate to RSUs granted on 10/15/2024, with 25% vesting on 10/15/2025. The remaining RSUs vest quarterly in equal 6.25% installments through 10/15/2028, subject to continued service.
Clover Health Investments, Corp. (CLOV) reported an insider transaction on a Form 4. Officer Jamie L. Reynoso (CEO, Medicare Advantage) had 71,432 shares of Class A Common Stock automatically withheld on 10/15/2025 to cover taxes from RSU vesting, at a transaction price of $2.8 per share (Code F).
Following this tax withholding, the insider beneficially owns 2,971,740 shares, held directly. The RSUs were granted on 10/15/2024; 25% vested on 10/15/2025. The remaining RSUs vest quarterly in equal 6.25% installments through 10/15/2028, subject to continued service.
Clover Health Investments (CLOV) reported an insider equity transaction. The company’s General Counsel & Secretary filed a Form 4 showing a transaction on 10/15/2025 coded “F,” reflecting 57,249 Class A shares automatically withheld at $2.8 per share to satisfy taxes from RSU vesting. Following the transaction, the reporting person beneficially owns 1,405,835 shares directly.
The withholding stemmed from the vesting of 25% of RSUs granted on 10/15/2024. The remaining RSUs vest quarterly in equal 6.25% installments, with a final vesting date on 10/15/2028, subject to continued service.
Clover Health Investments (CLOV): Officer Form 4 filing. A company officer reported an automatic share withholding for taxes tied to RSU vesting. On 10/15/2025, 92,181 shares of Class A common stock were withheld (code F) at $2.80 due to the vesting of 25% of RSUs granted on 10/15/2024.
After this tax withholding, the officer reported 1,274,463 shares beneficially owned directly, plus 1,610,482 shares held indirectly by a family trust. The remaining RSUs vest quarterly in equal 6.25% installments through 10/15/2028, subject to continued service.
Clover Health Investments, Corp. furnished an update on quality ratings for its Medicare Advantage plans following the Centers for Medicare & Medicaid Services release of 2026 Star Ratings. CMS awarded the Company’s PPO Medicare Advantage plans 3.5 Stars and its HMO Medicare Advantage plan 4.0 Stars. These 2026 Star Ratings will be used by CMS to determine payments for the Company’s Medicare Advantage plans for the 2027 payment year. The details were provided in a press release furnished as an exhibit to this report.
Jamie L. Reynoso, listed as CEO, Medicare Advantage, reported two Section 16 transactions. On
FAQ
What is the current stock price of Clover Health Investments (CLOV)?
What is the market cap of Clover Health Investments (CLOV)?
